Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vytorin vs Atorvastatin in CHD and Diabetes
NCT00395603Phase 3Terminated
- Sponsor
- Organon & Co.
- Start
- Sep 2006
- Primary completion
- Jun 2007
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised trial of Vytorin in hypercholesterolemia, sponsored by Organon & Co. Primary endpoint: Percentage reduction in LDL-C at 6 weeks. Started Sep 2006; status: terminated.
02
Drugs
Vytorin
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00395603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395603.